Bio-Rad Labs (BIO) Tops Q2 EPS by $1.10, Misses on Revenue; Offers Q3 Guidance

Bio-Rad Labs (NYSE: BIO) reported Q2 EPS of $3.11, $1.10 better than the analyst estimate of $2.01. Revenue for the quarter came in at $638.5 million versus the consensus estimate of $645.79 million.

GUIDANCE:

Bio-Rad Labs sees Q3 2024 revenue of $638.5-681.1 million, versus the consensus of $661 million.

For earnings history and earnings-related data on Bio-Rad Labs (BIO) click here.

You May Also Be Interested In

• Cerebras CEO says investors misunderstood margin guidance
• Wendy's (WEN) July and January 10 calls active, share price up 30%
• AdaptHealth Corp. (AHCO) 6K contracts of September 10 calls active